Report #2859266

Received Sep 17, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Female
Age: Age unknown
State: —
Recovered: Recovered
Vaccinated: —
Onset: Aug 30, 2025
Days to onset: —
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
VARZOS	ZOSTER (SHINGRIX)	GLAXOSMITHKLINE BIOLOGICALS	2	UNK	—

Symptoms (2)

Loss of personal independence in daily activitiesMalaise

Symptom narrative

Malaise; This non-serious case was reported by a physician via sales rep and described the occurrence of malaise in a female patient who received Herpes zoster (Shingrix) for prophylaxis. Previously administered products included Shingrix with an associated reaction of no adverse event (First dose was received on an unknown date). On an unknown date, the patient received the 2nd dose of Shingrix. On 30-AUG-2025, an unknown time after receiving Shingrix, the patient experienced malaise (Verbatim: Malaise). On 01-SEP-2025, the outcome of the malaise was resolved (duration 2 days). The reporter considered the malaise to be related to Shingrix. The company considered the malaise to be related to Shingrix. Additional Information: GSK Receipt Date: 11-SEP-2025 HCP reported that the patient experienced malaise following the 2nd dose of Shingrix. The malaise had lasted 3 days over Labor Day weekend. It was not too bad, but it had ruined her weekend because she could not do anything. The patient did not have any issues with the first dose.